Author

Trevor Lissoos 1

1 Takeda Pharmaceuticals USA Inc,Deerfield,United States

Clinical Effectiveness of First-Line Anti-TNF Therapies and Second-Line Anti-TNF Therapy Post-Vedolizumab Discontinuation in Patients with Ulcerative Colitis or Crohn's Disease

Brian Bressler, Andres Yarur, Uri Kopylov, Marielle Bassel, Neil Brett, Trevor Lissoos, claudia lopez, Athanasios Natsios, Sumit Saha, Christina Kifnidi, Dirk Demuth, Haridarshan Patel, Gerassimos J. Mantzaris

Real-world Safety of Vedolizumab and Anti-TNF Therapies in Biologic-Naïve Ulcerative Colitis and Crohn's Disease Patients: Results from the EVOLVE study

Andres Yarur, Gerassimos J. Mantzaris, Uri Kopylov, Marielle Bassel, Neil Brett, Trevor Lissoos, claudia lopez, Athanasios Natsios, Christina Kifnidi, Sumit Saha, Dirk Demuth, Haridarshan Patel, Brian Bressler

RISK FACTORS FOR POSTOPERATIVE INFECTION AFTER LOWER GASTROINTESTINAL SURGERY IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: FINDINGS FROM A LARGE EPIDEMIOLOGICAL STUDY

Huifang Liang, Baoguo Jiang, Trevor Lissoos, Sudhakar Manne, Paul Dolin

Risk of reoccurrence of perianal fistulas in patients with Crohn's disease in the United States - A retrospective claims database study

Haridarshan Patel, Dominick Latremouille-Viau, Didier Serre, Trevor Lissoos, Kyle D. Null, Glynn Owen, Sarah Campbell-Hill

Item 1 - 4 / 4
1